Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.66 |
| ▸ | PTGFR | P43088 | 1/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30760662 | 0.91 | PTGER4 (0.66) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL32684932 | 0.91 | PTGER4 (0.67) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL32684881 | 0.91 | PTGER4 (0.55) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL196448 | 0.90 | PTGER4 (0.67) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL27139773 | 0.90 | PTGER4 (0.64) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL30760664 | 0.88 | PTGER4 (0.62) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| Tromethamine SCHEMBL22633156 | 0.87 | PTGER4 (0.62) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| Diethanolamine SCHEMBL28521337 | 0.85 | PTGER4 (0.60) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL1952882 | 0.84 | PTGER4 (0.71) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL32684714 | 0.83 | PTGER4 (0.56) | PTGER4PTGDRPTGER2TBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070918-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| EP-4577551-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024041559-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070918-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | PTGER1, PTGER4, PTGER2 | PTGER4 2/4885PTGDR 9/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.